News

A newly formed research network focused on Batten disease, a rare and inherited brain disorder that primarily affects…

Receiving the CUREator+ Dementia & Cognitive Decline funding marks a meaningful milestone in our journey to transform how…

MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap…

Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research

In this study, Redenlab has collaborated with the University of Melbourne, Monash University, and the Massachusetts Institute of…

Displayed at 95 Horatio Street, NY, PWSC argues that stuttering fosters deep listening and collaboration, aiming to transform…

MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a…

Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic…

Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination…

Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to…

Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance,…

Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that…

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA…

Redenlab are thrilled to announce that Dr. Peter Gibilisco has joined Redenlab’s advisory board. As a consumer advisor…

MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The…

Redenlab are partnering with Monash university, University of Melbourne, Eastern Health, and Invicta to deliver this world-first collaboration…

Angela Morgan, PhD, is a National Health and Medical Research Council Elizabeth Blackburn Fellow and leads the Speech…

L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays…

Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts…

Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate…

Scientists are turning to retinas as a potential screening target for early signs of Alzheimer’s, an incurable neurodegenerative…

Curebase, a company dedicated to democratizing clinical trials through a decentralized model is announcing its partnership with Redenlab,…

MEDIA RELEASEFRIDAY 15 JULY 2022 As many as 70% of people who experience stuttering have a family member…

Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal…

Redenlab’s latest iOS application provides state of the art audio capture, storage and analysis of speech and language…

Redenlab is contributing to a study sponsored by the Australian Department of Defence and The University of Melbourne…

Dr Amir Lahav hired as Chief of Digital Health and Strategy. He is a clinical neuroscientist and a…

Dr Geoff Stuart joins the Redenlab analytics team as Statistics Director. Geoff will be running the company’s clinical…

Redenlab are part of a successful consortium securing funding for training a new cohort of early career researchers…

Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma…

Professor Angela Morgan has been recognised for her outstanding leadership in advancing the diagnosis, prognosis and management of…

Redenlab CSO, Adam Vogel, will be presenting at the upcoming ERN-RND joint webinar with the European Acadamy of…

SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.

Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia

Welcome Dr Noffs. Gustavo brings a wealth of clinical and research experience to the team, making contributions to…

Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics…

Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by…

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled,…

Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in…

Learn more about the platforms and applications that Redenlab use for software development, documentation, and quality management that…

We are excited to announce that Redenlab Speech Scientists ranked top 1 AND 2 in the world for…

Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe…

In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and…